Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.

As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

The U.S. Food and Drug Administration recently approved a new class of non-opioid painkiller which one Lowcountry pharmacist is calling “revolutionary.” ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...